Abivax shares face pressure from cancer cases in ulcerative colitis trial
Statements (23)
- Bullish
Abivax shares are likely to continue rising as the trial update reduces concerns about cancer side effects from its ulcerative colitis drug.
- Bullish
Abivax stock surged 36% following an update to its obefazimod trial results that alleviated investor fears of cancer as a side effect of the drug.
- Bullish
Abivax shares are likely to continue rising as new clinical trial data supports the safety and effectiveness of its experimental ulcerative colitis treatment.
- Bullish
Abivax shares jumped 36% following new clinical trial data supporting ulcerative colitis drug obefazimod
- Bullish
Abivax stock rose 27% following an update to its cancer trial results
- Bullish
Abivax shares jumped 29% following favorable findings from the ABTECT Maintenance Part 2 study
- Bullish
Abivax shares are likely to continue rising following favorable results from the ABTECT Maintenance Part 2 study.
- Bullish
Abivax stock jumped 25% after it released fresh data on its lead drug for bowel disease
- Bullish
Abivax shares are likely to continue rising after the company released positive data on its lead drug for bowel disease.
- Bearish
Abivax SA shares suffered a spectacular collapse on Tuesday, cratering as much as 40% in Paris and New York.
- Bearish
Abivax shares are likely to face significant pressure due to the revelation of cancer cases undermining the company's best-in-class trial data.
- Bearish
Analyst downgraded Abivax following the trial results.
- Bearish
Abivax stock fell 40% on Tuesday after French biotech released late-stage trial data for its ulcerative colitis drug.
- Bearish
Abivax shares likely to fall further after the company's ulcerative colitis trial data showed cancer cases in the higher-dose group.
- Bearish
Abivax SA stock plunged in Tuesday premarket trading
- Bearish
Abivax shares are likely to continue declining as investors react to cancer cases reported in the Phase 3 maintenance study of its ulcerative colitis drug obefazimod.
- Bearish
Abivax suffered its largest intraday decline on record after reporting new data on its lead experimental inflammatory bowel disease drug.
- Bearish
Abivax shares are likely to face significant pressure as new trial data reveals cancer cases in its inflammatory bowel disease drug, causing a record intraday decline.
- Bearish
Abivax shares sink following key trial results for an inflammatory bowel drug
- Bearish
Abivax shares are likely to decline due to negative trial results for its inflammatory bowel drug.
- Bearish
Abivax shares are likely to face significant pressure as late-stage trial data for obefazimod showed poor results.
- Bearish
Abivax SA shares fell 32% after releasing late-stage maintenance trial data for obefazimod, an oral ulcerative colitis candidate.
- Bearish
Abivax shares are likely to face significant pressure due to the discovery of a potential cancer risk in its ulcerative colitis drug trial.